Compare Kohl's Corporation (KSS) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kohl's Corporation vs BIO-TECHNE Corp — how do they compare? Kohl's Corporation trades at $17.79 (market cap $1.99B), while BIO-TECHNE Corp trades at $71.71 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 5.6× Kohl's Corporation's market cap, and Kohl's Corporation pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| KSS | TECH | |
|---|---|---|
Market Cap | $1.99B | $11.16B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $72.12 |
52-Week Low | $10.42 | $43.31 |
Enterprise Value | $8.10B | $11.24B |
Dividend Yield | 2.85% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kohl's (KSS) trades at $17.59, up 1.68% on the day, with a bullish technical signal from moving averages. The stock shows deep value metrics with a P/E of 7.27 and P/B of 0.49, while recent earnings beats and a 10% jump in juniors sales (Zacks, 2026-06-30) signal operational improvements. Cash flow turned positive in 2026 projections at $276M, and the company is focusing on proprietary brands and value initiatives to drive traffic.
Outlook: Turnaround efforts under CEO Michael Bender show early progress, but revenue declines persist. Investment case hinges on margin expansion and market share recovery. Risks include intense retail competition and macroeconomic pressure on consumer spending. Analyst consensus is mixed with a $16.75 price target below current levels, suggesting cautious optimism amid execution uncertainty.
Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.
The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
